With a growing Transactions Team that is establishing itself as one of the leading independent practices in the market, Van Bael & Bellis (VBB), a Brussels-based international law firm, is pleased to announce the arrival of leading corporate M&A partner Caroline Daout alongside senior associates Virginie Lescot and Cedric Hauben as well as associates Jens Westerwoudt and Charles-Antoine du Bus.
Van Bael & Bellis, with co-counsel & De Bandt, assisted Alcogroup S.A. and its subsidiary Alcodis S.A. (“Alcogroup”) in the proceeding initiated in 2015 by the European Commission relating to the alleged ethanol benchmarks cartel which was closed with respect to Alcogroup on 23 May 2023.
Martedì 16 Maggio 2023, è stato ufficialmente pubblicato il testo finale del Regolamento (UE) 2023/956 relativo al meccanismo di adeguamento del carbonio alle frontiere (c.d. “CBAM”), avente lo scopo di prevenire il rischio di delocalizzazione delle imprese che producono merci c.d. ad alta intensità di carbonio.
Van Bael & Bellis’ (VBB) growing London office has established a UK-based International Trade team that has attracted senior hires from Crowell & Moring and Ashurst.
Head of VBB Transactions Team Michel Bonne and Counsel Hannelore Matthys contributed the Belgium chapter to the recently published Chambers Global Practice Guide on Corporate M&A
Van Bael & Bellis and RRH Consultores, S.C. are pleased to announce that the first edition of the Mexico City Investment Arbitration Days will take place in person on 18-19 May 2023
On 2 May 2023, the Belgian federal Minister of Social Security and Health published a brief policy document defining three proposed action points to deal with medicine shortages in the EU (see, attached “non-paper” – the Proposals). The Proposals seem to be backed by 18 further Member States, including France and Italy, and will be discussed on 4 and 5 May 2023 during an informal meeting of health ministers under the Swedish Presidency of the Council of the EU.
On 26 and 27 April 2023, the European Commission adopted a comprehensive package of proposed regulatory and intellectual property measures that will have a profound impact on the pharmaceutical industry for years to come.
